Literature DB >> 8824549

Cell proliferation and apoptosis during prostatic tumor xenograft involution and regrowth after castration.

F Bladou1, R L Vessella, K R Buhler, W J Ellis, L D True, P H Lange.   

Abstract

The biological mechanisms involved in androgen-dependent and -independent prostate cancer growth after castration were analyzed in the LuCaP 23.1 human prostate cancer xenograft model. Athymic mice (n = 82) bearing LuCaP 23.1 xenograft were castrated and tumors were harvested at different time points from day 0 to day 112 post castration. In each group of mice, tumor growth rate (TGR), serum PSA concentration, percentage of tumor cells incorporating bromodeoxyuridine (BUdR index), percentage of apoptotic tumor cells assessed by morphological analysis (apoptotic index), and presence of apoptosis-related DNA "ladder" were analyzed. Castration induced a significant decrease in TGR and serum PSA from day 1 to day 7, and a progressive increase in the 2 parameters from day 14 to day 112, heralding androgen-independent tumor relapse. Meanwhile the BUdR and apoptotic indexes varied as follows after castration: an increase was noted for both at day 3, a significant increase in apoptotic index with a decrease in BUdR index from day 5 to day 14, and a progressive decrease in apoptotic index while BUdR index remained at 50% of the pre-castration value from day 28 to day 112. DNA ladder was present sparsely in tumors grown in non-castrated hosts, universally present in tumors from day 1 to day 28 post castration, and frequent in tumors from day 56 to 112. Castration-induced effects in LuCaP 23.1 tumors were characterized by an increase in number of apoptotic cells and a decrease in proliferative activity. The androgen-independent tumor relapse after castration was associated with a low apoptotic index with no increase in proliferative activity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8824549     DOI: 10.1002/(SICI)1097-0215(19960917)67:6<785::AID-IJC6>3.0.CO;2-N

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  18 in total

1.  A mathematical investigation of the multiple pathways to recurrent prostate cancer: comparison with experimental data.

Authors:  Trachette L Jackson
Journal:  Neoplasia       Date:  2004 Nov-Dec       Impact factor: 5.715

2.  Inhibition of androgen-independent prostate cancer by estrogenic compounds is associated with increased expression of immune-related genes.

Authors:  Ilsa M Coleman; Jeffrey A Kiefer; Lisha G Brown; Tiffany E Pitts; Peter S Nelson; Kristen D Brubaker; Robert L Vessella; Eva Corey
Journal:  Neoplasia       Date:  2006-10       Impact factor: 5.715

3.  Population pharmacokinetic-pharmacodynamic modelling of the relationship between testosterone and prostate specific antigen in patients with prostate cancer during treatment with leuprorelin.

Authors:  Nelleke Snelder; Henk-Jan Drenth; Kirsten Riber Bergmann; Nolan David Wood; Mark Hibberd; Graham Scott
Journal:  Br J Clin Pharmacol       Date:  2019-04-03       Impact factor: 4.335

4.  Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block.

Authors:  Maitreyee K Jathal; Liqun Chen; Maria Mudryj; Paramita M Ghosh
Journal:  Immunol Endocr Metab Agents Med Chem       Date:  2011-06

Review 5.  Testosterone and prostate cancer: an evidence-based review of pathogenesis and oncologic risk.

Authors:  Jason E Michaud; Kevin L Billups; Alan W Partin
Journal:  Ther Adv Urol       Date:  2015-12

6.  The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft.

Authors:  J A Kiefer; R L Vessella; J E Quinn; A M Odman; J Zhang; E T Keller; P J Kostenuik; C R Dunstan; E Corey
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

7.  Androgen deprivation induces senescence characteristics in prostate cancer cells in vitro and in vivo.

Authors:  Jonathan A Ewald; Joshua A Desotelle; Dawn R Church; Bing Yang; Wei Huang; Timo A Laurila; David F Jarrard
Journal:  Prostate       Date:  2012-08-21       Impact factor: 4.104

8.  Progression to androgen-independent LNCaP human prostate tumors: cellular and molecular alterations.

Authors:  Jin-Rong Zhou; Lunyin Yu; Luiz F Zerbini; Towia A Libermann; George L Blackburn
Journal:  Int J Cancer       Date:  2004-07-20       Impact factor: 7.396

9.  Comparison of ACINUS, caspase-3, and TUNEL as apoptotic markers in determination of tumor growth rates of clinically localized prostate cancer using image analysis.

Authors:  Swaroop S Singh; Diana C Mehedint; O Harris Ford; D Antony Jeyaraj; Elena A Pop; Susan J Maygarden; Anastasia Ivanova; Rameela Chandrasekhar; Gregory E Wilding; James L Mohler
Journal:  Prostate       Date:  2009-11-01       Impact factor: 4.104

10.  A partial differential equation model and its reduction to an ordinary differential equation model for prostate tumor growth under intermittent hormone therapy.

Authors:  Youshan Tao; Qian Guo; Kazuyuki Aihara
Journal:  J Math Biol       Date:  2013-08-28       Impact factor: 2.259

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.